Cerclage for Short Cervix in Twin Pregnancy
(TWIN-UIC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether cervical cerclage (also known as cervical stitch, cervical encircling, or cervical banding) can prevent early birth in women pregnant with twins. It focuses on women without symptoms but with a cervix measuring 15mm or less, which increases the risk of preterm birth. Participants are divided into two groups: one receives cerclage and daily progesterone treatment, while the other takes only daily progesterone. Women pregnant with twins and diagnosed with a very short cervix might be suitable for this trial. As an unphased trial, this study offers a unique opportunity to contribute to research that could improve outcomes for women with similar conditions.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that cervical cerclage, a procedure for twin pregnancies with a short cervix, might improve outcomes. Some studies found that cerclage can lower the risk of early birth and increase the chances of healthy births. For instance, one study reported very high live birth rates for twins when cerclage was used, with some groups achieving rates as high as 100%.
However, earlier research produced mixed results, with some suggesting it might increase the risk of preterm birth (before 37 weeks). Despite this, more recent studies suggest that cerclage can be helpful for women with twin pregnancies and a short cervix.
Cervical cerclage is already used in other pregnancy situations, indicating a certain level of safety and understanding of its effects. For those considering joining a trial involving cerclage, these findings offer insight into its use and potential safety in humans.12345Why are researchers excited about this trial's treatments?
Cervical cerclage for twin pregnancies with a short cervix is unique because it provides mechanical support to the cervix, potentially preventing premature birth. Unlike standard treatments that rely solely on hormonal support like vaginal progesterone, cerclage physically reinforces the cervix. Researchers are excited because combining cerclage with vaginal progesterone might offer a dual approach—structural and hormonal—potentially improving outcomes for mothers carrying twins, who are at higher risk of preterm birth. This combination approach could bring new hope for better managing this challenging condition.
What evidence suggests that cervical cerclage might be an effective treatment for preventing preterm birth in twin pregnancies with a short cervix?
This trial will compare the effectiveness of cervical cerclage combined with vaginal progesterone to vaginal progesterone alone in twin pregnancies with a short cervix. Research has shown that cervical cerclage can help in such pregnancies. Studies have found that it may lower the risk of early preterm birth and improve newborn health. Specifically, cerclage has been associated with reducing the chances of giving birth before 28, 32, and 34 weeks of pregnancy. This treatment might be especially helpful when the cervix is very short. Overall, evidence suggests that cerclage could improve pregnancy outcomes in these cases.46789
Who Is on the Research Team?
Amanda Roman, MD
Principal Investigator
Thomas Jefferson University
Are You a Good Fit for This Trial?
This trial is for women over 18 with twin pregnancies, specifically those who have a short cervical length (≤15mm) detected by ultrasound between 16 and nearly 24 weeks of gestation. Participants should not show symptoms. Women with more than two babies, certain twin complications like Twin-twin transfusion syndrome, or any listed conditions that could complicate pregnancy are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive cervical cerclage and/or daily vaginal progesterone from diagnosis of short cervix to 36 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cervical cerclage
Cervical cerclage is already approved in European Union, United States, Canada for the following indications:
- Prevention of preterm birth in women with cervical insufficiency
- Prevention of preterm birth in women with short cervical length
- Prevention of preterm birth in women with cervical insufficiency
- Prevention of preterm birth in women with short cervical length
- Prevention of preterm birth in women with cervical insufficiency
- Prevention of preterm birth in women with short cervical length
Find a Clinic Near You
Who Is Running the Clinical Trial?
Thomas Jefferson University
Lead Sponsor
Federico II University
Collaborator